NCT02172872 2023-02-15
"InDACtion" vs "3+7" Induction in AML
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
Clinical Trials
11 trialsNCT05339204 2022-04-21
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
National Research Center for Hematology, Russia
Phase NA Unknown
NCT01587430 2014-04-07
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
National Research Center for Hematology, Russia
Phase 4 Unknown
NCT00091234 2012-07-24
AML-19
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Unknown
NCT00838240 2012-07-20
AML-14A
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Unknown
NCT00887042 2012-03-26
Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
The Korean Society of Pediatric Hematology Oncology
Phase 1/2 Unknown
NCT01556477 2012-03-16
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Nordic MDS Group
Phase 2 Unknown
NCT01146977 2010-06-22
CBF(+)AML
Cooperative Study Group A for Hematology
Phase 2 Unknown
NCT01145846 2010-06-17
AIvsAD
Cooperative Study Group A for Hematology
Phase 3 Unknown
NCT00559221 2008-10-15
FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML
Cooperative Study Group A for Hematology
Phase 2 Unknown
NCT00529880 2007-09-27
Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML
Cooperative Study Group A for Hematology
Phase 2 Unknown